Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A9ED
|
|||
| Former ID |
DNC000387
|
|||
| Drug Name |
Carazolol
|
|||
| Synonyms |
Carazolol; 57775-29-8; Conducton; Suacron; corazolol; Carazolol [INN:BAN]; 1-((9H-Carbazol-4-yl)oxy)-3-(isopropylamino)propan-2-ol; Carazololum [INN-Latin]; CCRIS 1047; Conducton hydrochloride; 1-(Carbazol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(9H-carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol; EINECS 260-945-1; BRN 3620576; BM-51052; BM 51052; CHEMBL324665; 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(4-Carbazolyloxy)-3-isopropylamino-2-propanol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N2O2
|
|||
| Canonical SMILES |
CC(C)NCC(COC1=CC=CC2=C1C3=CC=CC=C3N2)O
|
|||
| InChI |
1S/C18H22N2O2/c1-12(2)19-10-13(21)11-22-17-9-5-8-16-18(17)14-6-3-4-7-15(14)20-16/h3-9,12-13,19-21H,10-11H2,1-2H3
|
|||
| InChIKey |
BQXQGZPYHWWCEB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 57775-29-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6685022, 7978853, 8194800, 15468496, 43128022, 50022846, 51091918, 57318337, 79557571, 85208998, 91611495, 103089481, 103153519, 103331481, 103937132, 104351190, 117613301, 126671688, 127555400, 134339829, 135029386, 135650054, 136161295, 137024393, 137251459, 162185417, 162251286, 162863557, 164786782, 172089152, 179150703, 184545382, 206246514, 223674687, 223704591, 226457254, 226457255, 250061443, 251890234, 252359210, 252390123
|
|||
| ChEBI ID |
CHEBI:135261
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Target Info | Agonist | [2] |
| Adrenergic receptor beta-3 (ADRB3) | Target Info | Agonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Gap junction | ||||
| Salivary secretion | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta1 adrenergic receptor signaling pathway | ||||
| Beta3 adrenergic receptor signaling pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 569). | |||
| REF 2 | Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.